```html

Kawasaki Disease (Incomplete) – A Patient‑Friendly Guide

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis that predominantly affects medium‑size arteries, especially the coronary arteries. When the classic clinical criteria are not fully met, the condition is called incomplete (or atypical) Kawasaki disease. Incomplete KD accounts for roughly 15‑30% of all cases, making early recognition crucial because delayed treatment raises the risk of serious heart complications.

• Age group: Most common in children under 5 years, with a peak incidence at 18‑24 months.
• Gender: Boys are affected about 1.5‑2 times more often than girls.
• Geography: Highest incidence in East Asian populations (Japan, Korea, Taiwan). In the United States, the CDC estimates ~19,000 new cases annually, with an incidence of 19–25 per 100,000 children < 5 years.
• Ethnicity: Children of Asian ancestry have a 2–3‑fold higher risk, but KD occurs worldwide.

Symptoms

Complete Kawasaki disease is defined by fever lasting ≥5 days plus at least four of the five principal clinical features. In incomplete KD, fever is present, but fewer than four classic signs appear. Clinicians rely on supplemental laboratory and echocardiographic findings to make the diagnosis.

Core features (may be partial in incomplete KD)

• Fever: Persistent high‑grade fever (often >38.5 °C) that does not respond to standard antipyretics.
• Conjunctival injection: Bright red, non‑purulent eyes without crusting.
• Oral changes: Strawberry‑like tongue, cracked lips, diffuse erythema of the oral mucosa.
• Peripheral extremity changes: Swelling or erythema of hands/feet, later desquamation (peeling) of fingertips and toes.
• Polymorphous rash: Often non‑specific, can be maculopapular, erythema multiforme‑like, or scarlatiniform.
• Cervical lymphadenopathy: Typically a single, >1.5 cm node, firm and non‑tender.

Additional clues that raise suspicion for incomplete KD

• Extremity edema or erythema that appears before rash.
• “Bilateral non‑exudative conjunctivitis” without discharge.
• Laboratory evidence of systemic inflammation (see Diagnosis section).
• Echocardiographic signs of coronary artery abnormalities despite missing clinical criteria.

Causes and Risk Factors

The exact trigger for Kawasaki disease remains unknown. Current research suggests a multifactorial model involving genetic susceptibility, environmental exposures, and an abnormal immune response.

• Genetics: Polymorphisms in genes related to immune regulation (e.g., ITPKC, CASP3, FCGR2A) increase risk. Siblings of a child with KD have a 10‑fold higher chance of developing the disease.
• Infectious agents: Seasonal peaks (winter–early spring) and occasional clustering hint at a viral or bacterial trigger, but no single pathogen has been confirmed.
• Environmental factors: Exposure to wood smoke, wind‑blown dust, or certain pollutants may play a role.
• Age: Immature immune systems in toddlers make them more vulnerable.
• Sex: Male gender.

Diagnosis

Diagnosis of incomplete KD is clinical, supported by laboratory and imaging data. The American Heart Association (AHA) algorithm (2020) is widely used.

Step‑by‑step approach

1. Identify prolonged fever: ≥5 days of fever without an alternative explanation.
2. Assess for any of the five principal features. If 2–3 are present, proceed to supplemental testing.
3. Laboratory testing: Look for elevated inflammatory markers and other supporting abnormalities:
   • CRP ≥ 3 mg/dL or ESR ≥ 40 mm/h
   • White‑blood‑cell count > 15,000/µL (or < 4,000 in very young infants)
   • Platelet count > 450,000/µL after day 7
   • Anemia (Hb < 10 g/dL)
   • Elevated ALT, GGT, or low serum albumin (< 3.0 g/dL)
   • Urine sterile pyuria
4. Echocardiography: Performed within the first 10 days of illness. Findings that support KD include:
   • Coronary artery dilation (Z‑score ≥ 2.5)
   • Perivascular brightness (“hinge” sign)
   • Reduced left ventricular function
5. Exclusion of other diseases: Bacterial sepsis, toxic shock syndrome, viral exanthems, scarlet fever, drug reactions, and systemic juvenile idiopathic arthritis must be ruled out.

Key diagnostic criteria (AHA 2020)

Criterion	Complete KD	Incomplete KD
Fever ≥5 days	Yes	Yes
≥ 4 principal clinical features	Yes	No (≤ 3)
Elevated CRP/ESR	Often	Required for incomplete KD
Coronary artery changes on echo	May be present	Strong supportive evidence

Treatment Options

Early treatment (ideally within 10 days of fever onset) dramatically lowers the risk of coronary artery aneurysms—from ~25% to < 5%.

First‑line therapy

• Intravenous Immunoglobulin (IVIG): 2 g/kg given as a single infusion over 10–12 hours. Reduces inflammation and coronary artery damage.
• Aspirin: High‑dose (80–100 mg/kg/day) divided every 6 hours until the fever resolves, then switched to low‑dose (3–5 mg/kg/day) for anti‑platelet effect, continued for 6–8 weeks or longer if coronary abnormalities persist.

Adjunctive & rescue therapies (for IVIG‑non‑responders)

• Second dose of IVIG: Re‑infusion 2 g/kg after 24‑48 h if fever persists.
• Corticosteroids: Methylprednisolone 30 mg/kg/day for 1–3 days followed by oral prednisone taper; recommended when risk scores (e.g., Kobayashi) predict IVIG resistance.
• Infliximab (anti‑TNFα): 5–10 mg/kg IV; effective in refractory cases.
• Cyclosporine or Anakinra (IL‑1 blockade): Considered in severe, resistant disease.

Supportive measures

• Fluid management to maintain adequate hydration.
• Antipyretics (acetaminophen) for comfort.
• Monitoring for cardiac ischemia (ECG, cardiac enzymes) if symptoms suggest.

Long‑term follow‑up

Patients with normal coronary arteries at 6 weeks typically resume standard pediatric care. Those with persistent dilation or aneurysms need lifelong cardiology surveillance, antiplatelet or anticoagulant therapy (e.g., low‑dose aspirin ± warfarin or clopidogrel), and lifestyle counseling.

Living with Kawasaki disease (incomplete)

While most children recover fully, the disease can be stressful for families. Below are practical tips for daily management.

• Medication adherence: Keep a medication calendar; set alarms for aspirin dosing.
• Follow‑up appointments: Schedule echocardiograms at 2 weeks, 6 weeks, and then as directed by the cardiologist.
• Activity restriction: During the acute phase, limit vigorous play and contact sports until fever resolves and platelet counts normalize.
• Hydration and nutrition: Encourage fluids and a balanced diet; avoid dehydration which can worsen coronary strain.
• Watch for skin changes: Peeling of fingertips is normal but should not be confused with infection.
• School re‑entry: Provide teachers with a brief note outlining the child's condition, medication schedule, and any activity limitations.
• Emotional support: Join support groups (e.g., Kawasaki Disease Foundation) and discuss concerns with a pediatric psychologist if anxiety arises.
• Vaccinations: Live vaccines (e.g., MMR, varicella) should be deferred for 4 weeks after IVIG infusion to avoid reduced efficacy.

Prevention

Because the exact cause is unknown, specific primary prevention is not possible. However, general health measures can reduce the overall risk of infections that might trigger an abnormal immune response.

• Hand hygiene and routine cleaning of toys and surfaces.
• Timely treatment of upper‑respiratory infections; avoid unnecessary antibiotic use.
• Maintain up‑to‑date routine vaccinations.
• Prompt medical evaluation for any fever lasting >3 days in a child under 5 years.

Complications

If not recognized and treated promptly, Kawasaki disease can lead to serious, sometimes life‑threatening, complications.

• Coronary artery aneurysms: Present in 15‑25% of untreated cases; can progress to thrombosis, myocardial infarction, or sudden cardiac death.
• Myocarditis / Myocardial dysfunction: May cause heart failure during the acute phase.
• Valvular regurgitation: Typically mild, involving the mitral or aortic valve.
• Peripheral arterial aneurysms: Rare, may affect the brachial or femoral arteries.
• Neurological involvement: Irritability, aseptic meningitis, or facial nerve palsy.
• Gastrointestinal complications: Hepatomegaly, gallbladder hydrops, or abdominal pain mimicking surgical abdomen.
• Long‑term sequelae: Early‑onset coronary artery disease, need for revascularization or cardiac transplantation in severe cases.

When to Seek Emergency Care

---

Sources: American Heart Association (2020 Kawasaki Disease Guideline); Mayo Clinic; Centers for Disease Control and Prevention (CDC) KD Surveillance Reports 2022‑2024; National Institutes of Health (NIH) – National Heart, Lung, and Blood Institute; World Health Organization (WHO); Cleveland Clinic; peer‑reviewed articles in The Lancet and JAMA Cardiology.

```